Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance
James A. McCubrey(East Carolina University), Alberto M. Martelli(University of Bologna), Jakob Troppmair(Innsbruck Medical University), Stephen L. Abrams(East Carolina University), Giovanni Ligresti(Boston University), Massimo Libra(University of Catania), Camilla Evangelisti(University of Bologna), Sarah A Molton(Cancer Research Institute), Ellis W.T. Wong(Greenville College), Negin Misaghian(East Carolina University), Ferdinando Nicoletti(University of Catania), Martin McMahon(University of Utah), Linda S. Steelman(East Carolina University), Jörg Bäsecke(University of Göttingen)
Cited by 80
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.
|The Journal of Experimental Medicine|1984|1.1k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878